Search

Displaying results 851 - 860 of 5383 in total
  1. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    US in December 2021. … It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms.

  2. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  3. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated … By inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013 … [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e.

  5. Drug

    Padimate A

    go.drugbank.com/drugs/DB11229
    ApprovedWithdrawn

    In Europe this chemical was withdrawn in 1989 for unstated reasons and in the US it was never approved for use in sunscreens.

  6. Drug

    Cupric sulfate

    go.drugbank.com/drugs/DB06778
    Approved

    The average daily intake of copper in the USA is approximately 1 mg Cu with the diet being a primary source [A32221]. … Cupric sulfate is a salt created by treating cupric oxide with sulfuric acid.

  7. Drug

    Tryptophan

    go.drugbank.com/drugs/DB00150
    ApprovedInvestigationalNutraceuticalWithdrawn

    It is a precursor of serotonin (hence its use as an antidepressant and sleep aid). It can be a precursor to niacin, albeit inefficiently, in mammals.

  8. Drug

    Terbinafine

    go.drugbank.com/drugs/DB00857
    ApprovedInvestigationalVet approved

    [A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall

    Categories: Antifungals for Topical Use, Antifungals for Systemic Use
  9. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured … In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use.

  10. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    They are indicated for use as rescue therapy following use of high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid … Levoleucovorin, as the product Fusilev (FDA), has an additional indication for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal